Project 3: Predicting therapeutic sensitivity in cancer
项目 3:预测癌症治疗敏感性
基本信息
- 批准号:8866154
- 负责人:
- 金额:$ 40.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-19 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAntineoplastic AgentsBiological MarkersCandidate Disease GeneCellsChimeric ProteinsChromosomal translocationCodeComplementary DNAComplexComputer SimulationDataDependencyDevelopmentDiseaseDrug TargetingDrug resistanceEpigenetic ProcessEventEvolutionFibroblast Growth Factor ReceptorsFoundationsFutureGene ExpressionGene Expression ProfileGene FusionGenesGeneticGenetic VariationGenomeGenomicsGenotypeGlioblastomaGoalsHeterogeneityHumanImatinibLeadLesionLibrariesLinkLongevityMachine LearningMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of lungMethodsModelingMolecularMolecular ProfilingMolecular TargetMutationNatureOncogenicPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPlant RootsPopulationPrimary NeoplasmPropertyProtein Tyrosine KinaseRNA InterferenceRecurrenceReportingResearchResidual stateResistanceRoleScreening for cancerTestingTherapeuticTraininganticancer researchbasebcr-abl Fusion Proteinscancer cellcancer genomecancer genomicschemical propertycohortcombinatorialcomputer frameworkcomputerized toolsdrug discoverydrug sensitivityeffective therapyexome sequencinggene interactiongenetic variantimprovedinsightmathematical modelmelanomamutantnetwork modelsoverexpressionpersonalized cancer therapyprotein complexresistance mechanismresponsesimulationsmall moleculesuccesstargeted treatmenttherapeutic targettherapy resistanttranscriptome sequencingtumor
项目摘要
TITLE
Project 3: Predicting therapeutic sensitivity in cancer.
ABSTRACT
Somatic genetic alterations in cancer have been linked with response to targeted therapeutics and resistance
to therapy. Methods that model and predict therapeutic sensitivity of cancer can be extremely useful in the
development of more effective treatments. Our goal is to model, predict, and target therapeutic sensitivity and
resistance of cancer. Our proposed approach is to utilize 3-dimensional (3-D) models of glioblastoma
(gliomaspheres, GS) that recapitulate the nature of genetics lesions in primary tumors to experimentally
validate computational Machine Learning predictions based on genomic information. Our approach in Aim 1 is
to build a computational framework that incorporates genomic data, drug properties and responses, and known
drug targets and network models of pathways and protein complexes to predict the therapeutic response of 80
genomically annotated GSs. Then, in Aim 2 we will experimentally validate our computational predictions of
therapeutic sensitivity across the library of GSs, test combinatorial predictions, and examine the molecular
mechanisms by which candidate genes alter drug responses. Single or multi-lesion sensitivity will be evaluated
by RNA interference or cDNA overexpression. Finally, we will investigate the role of cell heterogeneity in the
mechanism of drug resistance at the single cell level using topological methods, developed in Project 2 and in
the Mathematical Core. The ultimate goal of our studies will be to uncover mechanistic insights into genotype-
dependent sensitivity to drugs or synthetic lethal relationships. Ultimately, our studies will deliver key
information for the development of multiple gene- and pathway-based biomarkers for personalized cancer
therapies.
标题
项目3:预测癌症的治疗敏感性。
摘要
癌症中的体细胞遗传改变与靶向治疗和耐药性的反应有关
接受治疗对癌症的治疗敏感性进行建模和预测的方法在癌症治疗中是非常有用的。
开发更有效的治疗方法。我们的目标是建模,预测和靶向治疗敏感性,
癌症的抵抗力。我们提出的方法是利用胶质母细胞瘤的三维(3-D)模型
(胶质瘤球,GS),其概括了原发性肿瘤中遗传学病变的性质,
验证基于基因组信息的计算机器学习预测。我们在目标1中的方法是
建立一个计算框架,结合基因组数据,药物特性和反应,
药物靶点和网络模型的途径和蛋白质复合物,以预测治疗反应的80
基因组注释的GS。然后,在目标2中,我们将通过实验验证我们的计算预测,
治疗敏感性在整个图书馆的GS,测试组合预测,并检查分子
候选基因改变药物反应的机制。将评价单病灶或多病灶敏感性
通过RNA干扰或cDNA过表达。最后,我们将研究细胞异质性在细胞分化中的作用。
在单细胞水平上使用拓扑方法的耐药性机制,在项目2和
数学核心我们研究的最终目标将是揭示基因型的机理-
对药物的依赖性敏感性或合成致命关系。最终,我们的研究将提供关键的
用于开发个性化癌症的多种基于基因和途径的生物标志物的信息
治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNA LASORELLA其他文献
ANNA LASORELLA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNA LASORELLA', 18)}}的其他基金
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
(PQB5)利用横截面基因组数据重建进化网络
- 批准号:
8687270 - 财政年份:2014
- 资助金额:
$ 40.33万 - 项目类别:
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
(PQB5)利用横截面基因组数据重建进化网络
- 批准号:
9274933 - 财政年份:2014
- 资助金额:
$ 40.33万 - 项目类别:
(PQB5) Reconstruction of Evolutionary Networks using Cross-Sectional Genomic Data
(PQB5)利用横截面基因组数据重建进化网络
- 批准号:
9042317 - 财政年份:2014
- 资助金额:
$ 40.33万 - 项目类别:
The Ureb-1 ubiquitin ligase in neural stem cells and cancer
神经干细胞和癌症中的 Ureb-1 泛素连接酶
- 批准号:
8102742 - 财政年份:2008
- 资助金额:
$ 40.33万 - 项目类别:
The Ureb-1 ubiquitin ligase in neural stem cells and cancer
神经干细胞和癌症中的 Ureb-1 泛素连接酶
- 批准号:
8303475 - 财政年份:2008
- 资助金额:
$ 40.33万 - 项目类别:
The Ureb-1 ubiquitin ligase in neural stem cells and cancer
神经干细胞和癌症中的 Ureb-1 泛素连接酶
- 批准号:
7648243 - 财政年份:2008
- 资助金额:
$ 40.33万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 40.33万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 40.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 40.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 40.33万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 40.33万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 40.33万 - 项目类别:














{{item.name}}会员




